Skip to content

Ezetimibe

Ezetimibe is a medication that reduces blood cholesterol levels by inhibiting the absorption of cholesterol in the small intestine. It is primarily used to lower LDL cholesterol, which is a risk factor for cardiovascular disease. By managing cholesterol levels, ezetimibe contributes to cardiovascular health and longevity.

Intelligence Profile

Safety Profile

Safety Profile of Ezetimibe

Known Side Effects
Ezetimibe is generally well-tolerated, but some commonly reported side effects include:

  • Headache
  • Diarrhea
  • Upper respiratory tract infection
  • Joint pain
  • Fatigue

There are reports of more serious side effects, such as muscle pain and liver enzyme abnormalities, especially when used in combination with statins.

Contraindications
Patients with known hypersensitivity to ezetimibe should not use the drug. Additionally, it should be used cautiously or avoided in individuals with moderate to severe liver impairment due to potential liver-related side effects.

Drug Interactions

  • Statins: When ezetimibe is combined with statins, there is an increased risk of muscle-related side effects, including rhabdomyolysis.
  • Cyclosporine: There is potential for increased exposure to cyclosporine, requiring careful monitoring of cyclosporine levels.
  • Bile Acid Sequestrants: These can decrease the bioavailability of ezetimibe if taken concurrently. It is advised to administer ezetimibe at least two hours before or four hours after bile acid sequestrants.

Populations to Avoid

  • Pregnancy and Nursing Mothers: Safety has not been established in these groups, so ezetimibe should be avoided unless clearly necessary.
  • Children: Limited evidence on safety and efficacy in pediatric populations; caution is advised.
  • Elderly: Increased sensitivity to the drug cannot be ruled out, necessitating close monitoring.
  • Liver Dysfunction: Patients with moderate-to-severe hepatic impairment should avoid ezetimibe due to potential liver adverse effects.

Additional Considerations
Evidence regarding severe muscle-related disorders, such as immune-mediated necrotizing myopathy, is emerging, particularly in combination therapies (specifically with statins). The case report suggests a possible link, though robust evidence is sparse.

Disclaimer
This information is intended for educational purposes only and should not be considered medical advice. For personal health concerns, consult a healthcare professional.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.